Therefore, based on the cytokine serum level, we concluded that the unspecific IFN immunotherapy could potentially modulate both pro- and anti-inflammatory mediators in patients with pancreatic carcinoma. This evidence concerns the gene IFNA1 and exocrine pancreatic carcinoma.